Johannes has over 20 years of target validation and drug discovery experience in neurodegeneration, psychiatry, and metabolic diseases. Most recently Johannes was the Director of Neuro-pharmacology at Takeda San Diego. He has lead teams that filed 4 IND filings on first-in-class targets with two of these filings in phase 2 and 3 stages of development.'